Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Maintenance After Autologous Transplant for NHL
NCT01103388Phase 3Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2003
- Primary completion
- Apr 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression Free Survival at 2 years. Started Aug 2003; status: terminated.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01103388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01103388.